Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Ongoing entities : Teva pharmaceutical industries ltd save search
Intellia and Regeneron Announce Initial Data from the Cardiomyopathy Arm of Ongoing Phase 1 Study of NTLA-2001, an Investigational CRISPR Therapy for the Treatment of Transthyretin (ATTR) Amyloidosis
Published: 2022-09-16 (Crawled : 12:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: 0.74%
H: 0.91%
C: -0.74%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: -0.52%
H: 0.0%
C: 0.0%
REGN | $896.27 0.26% 0.25% 500K
|
Health Technology
|
| O: 0.62%
H: 1.12%
C: 0.01%
NTLA | $21.57 1.17% 1.16% 1.4M
|
Health Technology
|
| O: -3.76%
H: 0.36%
C: -0.44%
ntla-2001 treatment ongoing crispr therapy study
Regeneron and Alnylam Report Promising Data from Ongoing Phase 1 Study of ALN-HSD in NASH Patients and Healthy Volunteers
Published: 2022-09-15 (Crawled : 13:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: 1.6%
H: 0.0%
C: -6.5%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 0.4%
H: 0.84%
C: 0.37%
REGN | $896.27 0.26% 0.25% 500K
|
Health Technology
|
| O: -0.41%
H: 3.27%
C: 1.6%
ALNY | $144.315 -0.58% -0.59% 700K
|
Health Technology
|
| O: -0.9%
H: 2.16%
C: 1.01%
ongoing report nash study phase 1
Alnylam and Regeneron Report Promising Data from Ongoing Phase 1 Study of ALN-HSD in NASH Patients and Healthy Volunteers
Published: 2022-09-15 (Crawled : 12:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: 1.6%
H: 0.0%
C: -6.5%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 0.4%
H: 0.84%
C: 0.37%
REGN | $896.27 0.26% 0.25% 500K
|
Health Technology
|
| O: -0.41%
H: 3.27%
C: 1.6%
ALNY | $144.315 -0.58% -0.59% 700K
|
Health Technology
|
| O: -0.9%
H: 2.16%
C: 1.01%
ongoing report nash study phase 1
Update on ongoing Dupixent® (dupilumab) chronic spontaneous urticaria Phase 3 program
Published: 2022-02-18 (Crawled : 09:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -0.23%
H: 0.0%
C: -6.31%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: -0.47%
H: 0.77%
C: -0.23%
REGN | $896.27 0.26% 0.25% 500K
|
Health Technology
|
| O: -0.78%
H: 1.76%
C: -1.08%
dupixent ongoing program phase 3 urticaria
Regeneron and Sanofi Provide Update on Ongoing Dupixent® (dupilumab) Chronic Spontaneous Urticaria Phase 3 Program
Published: 2022-02-18 (Crawled : 07:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -0.23%
H: 0.0%
C: -6.31%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: -0.47%
H: 0.77%
C: -0.23%
REGN | $896.27 0.26% 0.25% 500K
|
Health Technology
|
| O: -0.78%
H: 1.76%
C: -1.08%
dupixent ongoing program phase 3 urticaria
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.